1. Bender DS., Skodol AE. Borderline personality as a self-other representational disturbance. J Personal Disord. 2007;21:500–517. [PubMed] [Google Scholar]
2. Choi-Kain LW., Gunderson JG. Mentalization: ontogeny, assessment, and application in the treatment of borderline personality disorder. Am J Psychiatry. 2008;165:1127–1135. [PubMed] [Google Scholar]
3. Fonagy P., Luyten P. A developmental, mentalization-based approach to the understanding and treatment of borderline personality disorder. Dev Psychopathol. 2009;21:1355–1381. [PubMed] [Google Scholar]
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Ed, Text Revision. Washington, DC: American Psychiatric Association; 2000 [Google Scholar]
5. Black DW., Blum N., Pfohl B., Hale N. Suicidal behavior in borderline personality disorder: prevalence, risk factors, prediction, and prevention. J Personal Disord. 2004;18:226–239. [PubMed] [Google Scholar]
6. Brodsky BS., Groves SA., Oquendo MA., Mann JJ., Stanley B. Interpersonal precipitants and suicide attempts in borderline personality disorder. Suicide Life Threat Behav. 2006;36:313–322. [PubMed] [Google Scholar]
7. Jovev M., Jackson HJ. The relationship between borderline personality disorder, life events, and functioning in an Australian psychiatric sample. J Personal Disord. 2006;20:205–217. [PubMed] [Google Scholar]
8. Stiglmayr CE., Ebner-Priemer UW., Bretz J., et al Dissociative symptoms are positively related to stress in borderline personality disorder. Acta Psychiatr Scand. 2008;117:139–147. [PubMed] [Google Scholar]
9. Grant BF., Chou SP., Goldstein RB., et al Prevalence, correlates, disability, and comorbidity of DSM-IV borderline personality disordenresults from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2008;69:533–545. [PMC free article] [PubMed] [Google Scholar]
10. Gross R., Olfson M., Gameroff M., et al Borderline personality disorder in primary care. Arch Intern Med. 2002;162:53–60. [PubMed] [Google Scholar]
11. Skodol A., Gunderson J., McGlashan T., et al Functional Impairment in patients with schizotypal, borderline, avoidant, and obsessive-compulsive personality disorders. Am J Psychiatry. 2002;159:276–283. [PubMed] [Google Scholar]
12. Lieb K., Zanarini MC., Schmahl C., Linehan MM., Bohus M. Borderline personality disorder. Lancet. 2004;364:453–461. [PubMed] [Google Scholar]
13. Zanarini MC., Frankenburg FR., Khera GS., Bleichmar J. Treatment histories of borderline inpatients. Compr Psychiatry. 2001;42:144–150. [PubMed] [Google Scholar]
14. Gunderson JG., Lyons-Ruth K. BPD's interpersonal hypersensitivity phenotype:a gene-environment-developmental model. J Personal Disord. 2008;22:22–41. [PMC free article] [PubMed] [Google Scholar]
15. Judd PH. Neurocognitive impairment as a moderator in the development of borderline personality disorder. Dev Psychopathol. 2005;17:1173–1196. [PubMed] [Google Scholar]
16. Luyten P., Blatt SJ. Integrating theory-driven and empirically-derived models of personality development and psychopathology: a proposal for DSM-V. Clin Psychol Rev. 2011;31:52–68. [PubMed] [Google Scholar]
17. Steele H., Siever U. An attachment perspective on borderline personality disorder:advances in gene-environment considerations. Curr Psychiatry Rep. 2010;12:61–67. [PubMed] [Google Scholar]
18. Choi-Kain LW., Zanarini MC., Frankenburg FR., Fitzmaurice GM., Reich DB. A longitudinal study of the 10-year course of interpersonal features in borderline personality disorder. J Personal Disord. 2010;24:365–376. [PMC free article] [PubMed] [Google Scholar]
19. Zanarini MC., Frankenburg FR., Reich DB., Silk KR., Hudson Jl., McSweeney LB. The subsyndromal phenomenology of borderline personality disorders 10-year follow-up study. Am J Psychiatry. 2007;164:929–935. [PubMed] [Google Scholar]
20. Zanarini MC., Frankenburg FR., Reich DB., Fitzmaurice G. The 10-year course of psychosocial functioning among patients with borderline personality disorder and axis II comparison subjects. Acta Psychiatr Scand. 2010;122:103–109. [PMC free article] [PubMed] [Google Scholar]
21. Gunderson JG., Stout RL., McGlashan TH., et al Ten-year course of borderline personality disorder: psychopathology and function from the collaborative longitudinal personality disorders study. Arch Gen Psychiatry. 2011;68:827–837. [PMC free article] [PubMed] [Google Scholar]
22. Ripoll LH., Triebwasser J., Siever U. Evidence-based pharmacotherapy for personality disorders. Int J Neuropsychopharmacol. 2011;15:1–32. [PubMed] [Google Scholar]
23. Abraham PF., Calabrese JR. Evidence-based pharmacologic treatment of borderline personality disorder: a shift from SSRIs to anticonvulsants and atypical antipsychotics? J Affect Disord. 2008;111:21–30. [PubMed] [Google Scholar]
24. Bellino S., Rinaldi C., Bozzatello C., Bogetto F. Pharmacotherapy of borderline personality disorders systematic review for publication purpose. Curr Med Chem. 2011;18:3322–3229. [PubMed] [Google Scholar]
25. Ingenhoven T., Lafay P., Rinne T., Passchier J., Duivenvoorden H. Effectiveness of pharmacotherapy for severe personality disorders: metaanalyses of randomized controlled trials. J Clin Psychiatry. 2010;71:14–25. [PubMed] [Google Scholar]
26. Lieb K., Vollm B., Rucker G., Timmer A., Staffers JM. Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Br J Psychiatry. 2010;196:4–12. [PubMed] [Google Scholar]
27. Mercer D., Douglass AB., Links PS. Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: effectiveness for depression and anger symptoms. J Personal Disord. 2009;23:156–174. [PubMed] [Google Scholar]
28. Saunders EF., Silk KR. Personality trait dimensions and the pharmacological treatment of borderline personality disorder. J Clin Psychopharmacol. 2009;29:461–467. [PubMed] [Google Scholar]
29. Staffers J., Vollm BA., Rucker G., Timmer A., Huband N., Lieb K. Pharmacological interventions for borderline personality disorder. Cochrane Database SystRev. 2010;6:CD005653. [PMC free article] [PubMed] [Google Scholar]
30. Frankenburg FR., Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry. 2002;63:442–446. [PubMed] [Google Scholar]
31. Zanarini MC., Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2001;62:849–854. [PubMed] [Google Scholar]
32. Salzman C., Wolfson AN., Schatzberg A., et al Effects of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol. 1995;15:23–29. [PubMed] [Google Scholar]
33. Rifkin A., Quitkin F., Carrillo C., Blumberg AG., Klein DF. Lithium carbonate in emotionally unstable character disorder. Arch Gen Psychiatry. 1972;27:519–523. [PubMed] [Google Scholar]
34. Battaglia J., Wolff TK., Wagner-Johnson DS., Rush AJ., Carmody TJ., Basco MR. Structured diagnostic assessment and depot f luphenazine treatment of multiple suicide attempters in the emergency department. Int Clin Psychopharmacol. 1999;14:361–372. [PubMed] [Google Scholar]
35. Coccaro EF., Kavoussi RJ. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry. 1997;54:1081–1088. [PubMed] [Google Scholar]
36. Goldberg SC., Schulz SC., Schulz PM., Resnick RJ., Hamer RM., Friedel RO. Borderline and schizotypal personality disorders treated with low-dose thiothixene vs. placebo. Arch Gen Psychiatry. 1986;43:680–686. [PubMed] [Google Scholar]
37. Montgomery SA., Roy D., Montgomery DB. The prevention of recurrent suicidal acts. Br J Clin Pharmacol. 1983;15:183S–188S. [PMC free article] [PubMed] [Google Scholar]
38. Serban G., Siegel S. Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol. Am J Psychiatry. 1984;141:1455–1458. [PubMed] [Google Scholar]
39. Soloff PH., George A., Nathan RS., et al Progress in pharmacotherapy of borderline disorders. Arch Gen Psychiatry. 1986;43:691–697. [PubMed] [Google Scholar]
40. Verkes RJ., van der Mast RC., Hengeveld MW., Tuyl JP., Zwinderman AH., Van Kempen GM. Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression. Am J Psychiatry. 1998;155:543–547. [PubMed] [Google Scholar]
41. Tritt K., Nickel C., Lahmann C., et al Lamotrigine treatment of aggression in female borderline patients: a randomized, double-blind, placebocontrolled study. J Psychopharmacol. 2005;19:287–291. [PubMed] [Google Scholar]
42. Zanarini MC., Frankenburg FR. Omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. Am J Psychiatry. 2003;160:167–169. [PubMed] [Google Scholar]
43. Zanarini MC., Frankenburg FR., Parachini EA. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry. 2004;7:903–907. [PubMed] [Google Scholar]
44. Bogenschutz MP., Nurnberg PH. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry. 2004;65:104–109. [PubMed] [Google Scholar]
45. Tyrer P., Silk KR. A comparison of UK and US guidelines for drug treatment in borderline personality disorder, int Rev Psychiatry. 2011;23:388–394. [PubMed] [Google Scholar]
46. Jariani M., Saaki M., Nazari H., Birjandi M. The effect of olanzapine and sertraline on personality disorder in patients with methadone maintenance therapy. Psychiatr Danub. 2010;22:544–547. [PubMed] [Google Scholar]
47. Shafti SS., Shahveisi B. Olanzapine versus haloperidol in the management of borderline personality disorders randomized double-blind trial. J Clin Psychopharmacol. 2010;30:44–47. [PubMed] [Google Scholar]
48. Bellino S., Paradiso E., Bozzatello P., Bogetto F. Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorders pilot study. J Psychopharmacol. 2010;24:333–339. [PubMed] [Google Scholar]
49. Adityanjee, Romine A., Brown E., Thuras P., Lee S., Schulz SC. Quetiapine in patients with borderline personality disorder: an open-label trial. Ann Clin Psychiatry. 2008;20:219–226. [PubMed] [Google Scholar]
50. Bellino S., Paradiso E., Bogetto F. Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: a pilot study. J Clin Psychiatry. 2006;67:1042–1046. [PubMed] [Google Scholar]
51. Van den Eynde F., Senturk V., Naudts K., et al Efficacy of quetiapine for impulsivity and affective symptoms in borderline personality disorder. J Clin Psychopharmacol. 2008;28:147–155. [PubMed] [Google Scholar]
52. Villeneuve E., Lemelin S. Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target. J Clin Psychiatry. 2005;66:1298–1303. [PubMed] [Google Scholar]
53. Bellino S., Paradiso E., Bogetto F. Oxcarbazepine in the treatment of borderline personality disorder: a pilot study. J Clin Psychiatry. 2005;66:1111–1115. [PubMed] [Google Scholar]
54. Miyaoka T., Furuya M., Yasuda H., Hayashia M., Inagaki T., Horiguchi J. Yigan san for the treatment of borderline personality disorder: an open-label study. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:150–154. [PubMed] [Google Scholar]
55. Hesse E. The Adult Attachment lnterview:Protocol, method of analysis, and empirical studies. In: Hesse E, ed. Handbook of Attachment, Second Edition: Theory, Research, and Clinical Applications. New York, NY:Guilford Press; 2008:552–598. [Google Scholar]
56. Agrawal HR., Gunderson J., Holmes BM., Lyons-Ruth K. Attachment studies with borderline patients: a review. Harv Rev Psychiatry. 2004;12:94–104. [PMC free article] [PubMed] [Google Scholar]
57. Coccaro EF., Kavoussi RJ., Hauger RL. Physiological responses to d-fenfluramine and ipsapirone challenge correlate with indices of aggression in males with personality disorder. Int Clin Psychopharmacol. 1995;10:177–179. [PubMed] [Google Scholar]
58. Coccaro EF., Siever LJ., Klar HM., Maurer G., et al Serotonergic studies in patients with affective and personality disordersxorrelates with suicidal and impulsive aggressive behavior. Arch Gen Psychiatry. 1989;46:587–599. [PubMed] [Google Scholar]
59. Evenden J. Impulsivity: a discussion of clinical and experimental findings. J Psychopharmacol. 1999;13:180–192. [PubMed] [Google Scholar]
60. Malone KM., Corbitt EM., Li S., Mann JJ. Prolactin response to fenfluramine and suicide attempt lethality in major depression. Br J Psychiatry. 1996;168:324–329. [PubMed] [Google Scholar]
61. New AS., Goodman M., Triebwasser J., Siever LJ. Recent advances in the biological study of personality disorders. Psychiatr Clin North Am. 2008;31:441–461. [PubMed] [Google Scholar]
62. New AS., Hazlett EA., Buchsbaum MS., et al Blunted prefrontal cortical 18fluorodeoxyglucose positron emission tomography response to metachlorophenylpiperazine in impulsive aggression. Arch Gen Psychiatry. 2002;59:621–629. [PubMed] [Google Scholar]
63. New AS., Trestman R., Mitropoulou V., et al Low prolactin response to fenfluramine in impulsive aggression. J Psychiatr Res. 2004;38:223–230. [PubMed] [Google Scholar]
64. New AS., Trestman R., Mitropoulou V., et al Serotonergic function and self-injurious behavior in personality disorder patients. Psychiatry Res. 1997;69:17–26. [PubMed] [Google Scholar]
65. Oquendo MA., Krunic A., Parsey RV., et al Positron emission tomography of regional brain metabolic responses to a serotonergic challenge in major depressive disorder with and without borderline personality disorder. Neuropsychopharmacology. 2005;30:1163–1172. [PubMed] [Google Scholar]
66. Pitchot W., Hansenne M., Pinto E., Reggers J., Fuchs S., Ansseau M. 5-Hydroxytryptamine 1A receptors, major depression, and suicidal behavior. Biol Psychiatry. 2005;58:854–58. [PubMed] [Google Scholar]
67. Samuelsson M., Jokinen J., Nordstrom AL., Nordstrom P. CSF 5-HIAA, suicide intent and hopelessness in the prediction of early suicide in male highrisk suicide attempters. Acta Psychiatr Scand. 2006;113:44–47. [PubMed] [Google Scholar]
68. Siever LJ., Buchsbaum MS., New AS., et al D,L-fenfluramine response in impulsive personality disorder assessed with [18F]fluorodeoxyglucose positron emission tomography. Neuropsychopharmacology. 1999;20:413–423. [PubMed] [Google Scholar]
69. Silva H., Iturra P., Solari A., et al Serotonin transporter polymorphism and fluoxetine effect on impulsiveness and aggression in borderline personality disorder. Actas Esp Psiquiatr. 2007;35:387–392. [PubMed] [Google Scholar]
70. American Psychiatric Association Practice guideline. Practice guideline for the treatment of patients with borderline personality disorder. American Psychiatric Association. Am J Psychiatry. 2001;158(10 suppl):1–52. [PubMed] [Google Scholar]
71 . Rinne T., van den Brink W., Wouters L., van Dyck R. SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry. 2002;159:2048–2054. [PubMed] [Google Scholar]
72. Soloff PH., George A., Nathan RS., Schulz PM., Ulrich RF., Perel JM. Amitryptiline and haloperidol in unstable and schizotypal borderline disorders. Psychopharmacol Bull. 1986;22:177–182. [PubMed] [Google Scholar]
73. Soloff PH., George A., Nathan RS., Schulz PM., Perel JM. Behavioral dyscontrol in borderline patients treated with amitryptiline. Psychopharmacol Bull. 1987;23:177–181. [PubMed] [Google Scholar]
74. Soloff PH., George A., Nathan RS., Schulz PM., Perel JM. Paradoxical effects of amitryptiline on borderline patients. Am J Psychiatry. 1986;143:1603–1605. [PubMed] [Google Scholar]
75. Ayduk O., Zayas V., Downey G., Cole AB., Shoda Y., Mischel W. Rejection sensitivity and executive controfjoint predictors of borderline personality features. J Res Pers. 2008;42:151–168. [PMC free article] [PubMed] [Google Scholar]
76. Staebler K., Helbing E., Rosenbach C., Renneberg B. Rejection sensitivity and borderline personality disorder. Clin Psychol Psychother. 2011;18:275–283. [PubMed] [Google Scholar]
77. Cornelius JR., Soloff PH., Perel JM., Ulrich RF. Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine. Am J Psychiatry. 1993;150:1843–1848. [PubMed] [Google Scholar]
78. Cowdry RW., Gardner DL. Pharmacotherapy of borderline personality disorderslprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry. 1988;45:111–119. [PubMed] [Google Scholar]
79. Parsons B., Quitkin FM., McGrath PJ., et al Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression. Psychopharmacol Bull. 1989;25:524–534. [PubMed] [Google Scholar]
80. Soloff PH., Cornelius J., George A., Nathan S., Perel JM., Ulrich RF. Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry. 1993;50:377–385. [PubMed] [Google Scholar]
81. Hazlett EA., Zhang J., New AS., et al Potentiated amygdala response to repeated emotional pictures in borderline personality disorder. Biol Psychiatry. 2012;72:448–56. [PMC free article] [PubMed] [Google Scholar]
82. Higgins GA., Enderlin M., Haman M., Fletcher PJ. The 5-HT2A receptor antagonist M100.907 attenuates motor and'impulsive-type' behaviours produced by NMDA receptor antagonism. Psychopharmacology (Berl). 2003;170:309–319. [PubMed] [Google Scholar]
83. Winstanley CA., Theobald DE., Dalley JW., Glennon JC., Robbins TW. 5HT2A and 5-HT2C receptor antagonists have opposing effects on a measure of impulsivity: interactions with global 5-HT depletion. Psychopharmacology (Berl). 2004;176:376–385. [PubMed] [Google Scholar]
84. Homberg JR. Serotonin and decision-making processes. Neurosci BiobehavRev. 2012;36:218–236. [PubMed] [Google Scholar]
85. Takahashi A., Quadros IM., de Almeida RM., Miczek KA. Behavioral and pharmacogenetics of aggressive behavior. Curr Top Behav Neurosci. 2012;12:73–138. [PMC free article] [PubMed] [Google Scholar]
86. Assadi SM., Yucel M., Pantelis C. Dopamine modulates neural networks involved in effort-based decision-making. Neurosci Biobehav Rev. 2009;33:383–393. [PubMed] [Google Scholar]
87. Nickel MK., Loew TH., Pedrosa Gil F. Aripiprazole in treatment of borderline patients, part ll:an 18-month follow-up. Psychopharmacology. 2007;191:1023–1026. [PubMed] [Google Scholar]
88. Nickel MK., Muehlbacher M., Nickel C., et al Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2006;163:833–838. [PubMed] [Google Scholar]
89. Linehan MM., McDavid JD., Brown MZ., Sayrs JH., Gallop RJ. Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorders double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2008;69:999–1005. [PubMed] [Google Scholar]
90. Soler J., Pascual JC., Campins J., et al Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry. 2005;162:1221–1224. [PubMed] [Google Scholar]
91. Schulz SC., Zanarini MC., Bateman A., et al Olanzapine for the treatment of borderline personality disordervariable dose 12 week randomised double-blind placebo-controlled study. Br J Psychiatry. 2008;193:485–492. [PubMed] [Google Scholar]
92. Zanarini MC., Schulz SC., Detke HC., et al A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12 week randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2011;72:1353–1362. [PubMed] [Google Scholar]
93. Zanarini MC., Schulz SC., Detke HC., et al Open-label treatment with olanzapine for patients with borderline personality disorder. J Clin Psychopharmacol. 2012;32:398–402. [PubMed] [Google Scholar]
94. Pascual JC., Soler J., Puigdemont D., et al Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study. J Clin Psychiatry. 2008;69:603–608. [PubMed] [Google Scholar]
95. Zanarini MC., Reichman CA., Frankenburg FR., Reich DB., Fitzmaurice G. The course of eating disorders in patients with borderline personality disorder: a 10-year follow-up study. Int J Eat Disord. 2010;43:226–232. [PMC free article] [PubMed] [Google Scholar]
96. Frankenburg FR., Zanarini MC. Obesity and obesity-related illnesses in borderline patients. J Personal Disord. 2006;20:71–80. [PubMed] [Google Scholar]
97. Bolton S., Gunderson JG. Distinguishing borderline personality disorder from bipolar disorder: differential diagnosis and implications. Am J Psychiatry. 1996;153:1202–1207. [PubMed] [Google Scholar]
98. Critchfield KL., Levy KN., Clarkin JF., Kernberg OF. The relational context of aggression in borderline personality disordenusing adult attachment style to predict forms of hostility. J Clin Psychol. 2008;64:67–82. [PubMed] [Google Scholar]
99. Gunderson JG. Disturbed relationships as a phenotype for borderline personality disorder. Am J Psychiatry. 2007;164:1637–1640. [PubMed] [Google Scholar]
100. Henry C., Mitropoulou V., New AS., Koenigsberg HW., Silverman J., Siever LJ. Affective instability and impulsivity in borderline personality and bipolar II disorders: similarities and differences. J Psychiatr Res. 2001;35:307–312. [PubMed] [Google Scholar]
101. Paris J. Borderline or bipolar? Distinguishing borderline personality disorder from bipolar spectrum disorders. Harv Rev Psychiatry. 2004;12:140–145. [PubMed] [Google Scholar]
102. Links PS., Steiner M., Boiago I., Irwin D. Lithium therapy for borderline patients:preliminary findings. J Personal Disord. 1990;4:173–181. [Google Scholar]
103. Gardner DL., Cowdry RW. Development of melancholia during carbamazepine treatment in borderline personality disorder. J Clin Psychopharmacol. 1986;6:236–239. [PubMed] [Google Scholar]
104. Gardner DL., Cowdry RW. Positive effects of carbamazepine on behavioral dyscontrol in borderline personality disorder. Am J Psychiatry. 1986;143:519–522. [PubMed] [Google Scholar]
105. de la Fuente JM., Lotstra F. Atrial of carbamazepine in borderline personality disorder. Eur Neuropsychopharmacol. 1994;4:479–486. [PubMed] [Google Scholar]
106. Loew TH., Nickel MK., Muehlbacher M., et al Topiramate treatment of women with borderline personality disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2006;26:61–66. [PubMed] [Google Scholar]
107. Loew TH., Nickel MK. Topiramate treatment of women with borderline personality disorder, part ll:an open 18-month follow-up. J Clin Psychopharmacol. 2008;28:355–357. [PubMed] [Google Scholar]
108. Nickel MK., Loew TH. Treatment of aggression with topiramate in male borderline patients, part II: 18-month follow-up. Eur Psychiatry. 2008;23:115–117. [PubMed] [Google Scholar]
109. Nickel MK., Nickel C., Kaplan P., et al Treatment of aggression with topiramate in male borderline patients:a double-blind, placebo-controlled study. Biol Psychiatry. 2005;57:495–499. [PubMed] [Google Scholar]
110. Nickel MK., Nickel C., Mitterlehner FO., et al Topiramate treatment of aggression in female borderline personality disorder patients: a doubleblind, placebo-controlled study. J Clin Psychiatry. 2004;65:1515–1519. [PubMed] [Google Scholar]
111. Reich DB., Zanarini MC., Bieri KA. A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder. Int Clin Psychopharmacol. 2009;24:270–275. [PubMed] [Google Scholar]
112. Leiberich F., Nickel MK., Tritt K., Pedrosa Gil F. Lamotrigine treatment of aggression in female borderline patients, part II: an 18-month follow-up. J. Psychopharmacol. 2008:805–808. [PubMed] [Google Scholar]
113. Hollander E., Swann AC., Coccaro EF., et al Impact of trait impulsivity and state aggression on divalproex vs. placebo response in borderline personality disorder. Am J Psychiatry. 2005;162:621–624. [PubMed] [Google Scholar]
114. Ziegenhorn AA., Roepke S., Schommer NC., et al Clonidine improves hyperarousal in borderline personality disorder with or without comorbid post-traumatic stress disorders randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2009;29:170–173. [PubMed] [Google Scholar]
115. Bandelow B., Schmahl C., Falkai P., Wedekind D. Borderline personality disorders dysregulation of the endogenous opioid system? Psychol Rev. 2010;117:623–636. [PubMed] [Google Scholar]
116. Stanley B., Siever LJ. The interpersonal dimension of borderline personality disorder: toward a neuropeptide model. Am J Psychiatry. 2010;167:24–39. [PMC free article] [PubMed] [Google Scholar]
117. Depue RA., Morrone-Strupinsky JV. A neurobehavioral model of aff illative bonding: implications for conceptualizing a human trait of affiliation. Behav Brain Sci. 2005;28:313–395. [PubMed] [Google Scholar]
118. Higham JP., Barr CS., Hoffman CL., Mandalaywala TM., Parker KJ., Maestripieri D. Mu opioid receptor variation, oxytocin levels, and maternal attachment in free-ranging rhesus macaques Macaca mulatta. Behav Neurosci. 2011;125:131–136. [PMC free article] [PubMed] [Google Scholar]
119. Troisi A., Frazzetto G., Carola V., et al Variation in the -opioid receptor gene (OPRM1 ) moderates the influence of early maternal care on fearful attachment. Soc. Cogn Affect Neurosci. 2012;7:542–547. [PMC free article] [PubMed] [Google Scholar]
120. Prossin AR., Love TM., Koeppe RA., Zubieta JK., Silk KR. Dysregulation of regional endogenous opioid function in borderline personality disorder. Am J Psychiatry. 2010;167:925–933. [PMC free article] [PubMed] [Google Scholar]
121. Bohus MJ., Landwehrmeyer GB., Stiglmayr CE., Limberger MF., Bohme R., Schmahl CG. Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disordersn open-label trial. J Clin Psychiatry. 1999;60:598–603. [PubMed] [Google Scholar]
122. Ebner-Priemer UW., Mauchnik J., Kleindienst N., et al Emotional learning during dissociative states in borderline personality disorder. J Psychiatry Neurosci. 2009;34:214–22. [PMC free article] [PubMed] [Google Scholar]
123. Saper JR. Borderline personality, opioids, and naltrexone. Headache. 2000;40:765–766. [PubMed] [Google Scholar]
124. Thurauf NJ., Washeim HA. The effects of exogenous analgesia in a patient with borderline personality disorder (BPD) and severe self-injurious behavior. Eur J Pain. 2000;4:107–109. [PubMed] [Google Scholar]
125. Philipsen A., Schmahl C., Lieb K. Naloxone in the treatment of acute dissociative states in female patients with borderline personality disorder. Pharmacopsychiatry. 2004;37:196–199. [PubMed] [Google Scholar]
126. Schmahl C., Kleindienst N., Limberger M., et al Evaluation of naltrexone for dissociative symptoms in borderline personality disorder, int Clin Psychopharmacol. 2012;27:61–68. [PubMed] [Google Scholar]
127. Bartz JA., Zaki J., Bolger N., Ochsner KN. Social effects of oxytocin in humans: context and person matter. Trends Cogn Sci. 2011;15:301–309. [PubMed] [Google Scholar]
128. De Dreu CKW., Greer LL., Van Kleef GA., Shalvi S., Handgraaf MJ. Oxytocin promotes human ethnocentrism . Proc Natl Acad Sci USA. 2011;108:1262–1266. [PMC free article] [PubMed] [Google Scholar]
129. Feldman R., Weller A., Zagoory-Sharon O., Levine A. Evidence for a neuroendocrinological foundation of human affiliation: plasma oxytocin levels across pregnancy and the postpartum period predict mother-infant bonding. Psychol Sci. 2007;18:965–970. [PubMed] [Google Scholar]
130. Bartz J., Simeon D., Hamilton H., et al Oxytocin can hinder trust and cooperation in borderline personality disorder. Soc Cogn Affect Neurosci. 2011;6:556–563. [PMC free article] [PubMed] [Google Scholar]
131. Simeon D., Bartz J., Hamilton H., et al Oxytocin administration attenuates stress reactivity in borderline personality disorder: a pilot study. Psychoneuroendocrinology. 2011;36:1418–1421 . [PubMed] [Google Scholar]
132. Simpson EB., Yen S., Costello E., et al Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. J Clin Psychiatry. 2004;65:379–385. [PubMed] [Google Scholar]
133. Grosjean B., Tsai GE. NMDA neurotransmission as a critical mediator of borderline personality disorder. J Psychiatry Neurosci. 2007;32:103–115. [PMC free article] [PubMed] [Google Scholar]
134. Diergaarde L., Schoffelmeer AN., De Vries TJ. Pharmacological manipulation of memory consolidation: towards a novel treatment of pathogenic memories. Eur J Pharmacol. 2008;585:453–457. [PubMed] [Google Scholar]
135. Steckler T., Risbrough V. Pharmacological treatment of PTSD—established and new approaches. Neuropharmacology. 2012;62:617–627. [PMC free article] [PubMed] [Google Scholar]
136. Pattij T., Vanderschuren LJ. The neuropharmacology of impulsive behaviour. Trends Pharmacol Sci. 2008;29:192–199. [PubMed] [Google Scholar]
137. Vinod KY., Hungund BL. Role of the endocannabinoid system in depression and suicide. Trends Pharmacol Sci. 2006;27:539–545. [PubMed] [Google Scholar]
138. Parolaro D., Realini N., Vigano D., Guidali C., Rubino T. The endocannabinoid system and psychiatric disorders. Exp Neurol. 2010;224:3–14. [PubMed] [Google Scholar]
139. Fitzgerald ML., Shobin E., Pickel VM. Cannabinoid modulation of the dopaminergic circuitry:implications for limbic and striatal output. Prog Neuropsychopharmacol Biol Psychiatry. 2012;38:21–29. [PMC free article] [PubMed] [Google Scholar]
140. de Bitencourt RM., Pamplona FA., Takahashi RN. A current overview of cannabinoids and glucocorticoids in facilitating extinction of aversive memories:potential extinction enhancers. Neuropharmacology. 2013;64:389–395. [PubMed] [Google Scholar]
141. Knoll AT., Carlezon WA Jr. Dynorphin, stress, and depression. Brain Res. 2010;1314:56–73. [PMC free article] [PubMed] [Google Scholar]
142. Carr GV., Bangasser DA., Bethea T., Young M., Valentino RJ., Lucki I. Antidepressant-like effects of kappa opioid receptor antagonists in Wistar Kyoto rats. Neuropsychopharmacology. 2010;35:752–763. [PMC free article] [PubMed] [Google Scholar]
143. Chartoff E., Sawyer A., Rachlin A., Potter D., Pliakas A., Carlezon WA. Blockade of kappa opioid receptors attenuates the development of depressive-like behaviors induced by cocaine withdrawal in rats. Neuropharmacology. 2012;62:167–76. [PMC free article] [PubMed] [Google Scholar]
144. Peters MF., Zacco A., Gordon J., et al Identification of short-acting K-opioid antagonists with anxiolytic-like activity. Eur J Pharmacol. 2011;661:27–34. [PubMed] [Google Scholar]
